Literature DB >> 14527778

Febrile urinary tract infection in men.

Peter Ulleryd1.   

Abstract

Febrile urinary tract infection (UTI) in adult men has received little attention in the literature, partly due to the low incidence compared with women. In a multidisciplinary project, infectious disease specialists, urologists and microbiologists studied the host-parasite interaction in men from Gothenburg with community-acquired febrile UTI. The results are discussed in the light of other similar studies and related to findings in women. Contrary to the traditional view, men and women with febrile UTI have very similar infecting bacterial species, host predispositions and treatment results. However, virulence expression differs in the infecting Escherichia coli in both sexes, besides the overt anatomical distinction including having a prostate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527778     DOI: 10.1016/s0924-8579(03)00228-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection.

Authors:  A Smithson; C Chico; J Ramos; C Netto; M Sanchez; J Ruiz; R Porron; M T Bastida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-15       Impact factor: 3.267

2.  Antibiotic resistance in uropathogenic e. Coli strains isolated from non-hospitalized patients in pakistan.

Authors:  Ihsan Ali; Neeraj Kumar; Safia Ahmed; Javid Iqbal Dasti
Journal:  J Clin Diagn Res       Date:  2014-09-20

3.  Intravenous Antibiotic Susceptibility for Urinary Tract Infection Prior to Emergency Department Discharge.

Authors:  Stacey Rewitzer; Josie Montgomery; Anne Zepeski; Lexie Finer; Brett A Faine
Journal:  Hosp Pharm       Date:  2020-05-31

4.  Association between past urinary tract infections and current symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Nicholas A Daniels; Carol L Link; Michael J Barry; John B McKinlay
Journal:  J Natl Med Assoc       Date:  2007-05       Impact factor: 1.798

5.  Antimicrobial Resistance Patterns and Dynamics of Extended-Spectrum β-Lactamase-Producing Uropathogenic Escherichia coli in Cusco, Peru.

Authors:  Steev Loyola; Fátima Concha-Velasco; Jimena Pino-Dueñas; Nancy Vasquez-Luna; Paola Juarez; Carlos Llanos; Guillermo Salvatierra; Jesus Tamariz; Andres G Lescano
Journal:  Antibiotics (Basel)       Date:  2021-04-22

6.  Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients.

Authors:  Jessina C McGregor; Miriam R Elman; David T Bearden; David H Smith
Journal:  BMC Fam Pract       Date:  2013-02-22       Impact factor: 2.497

7.  Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India.

Authors:  Savita Jadhav; Arif Hussain; Savita Devi; Ashutosh Kumar; Sana Parveen; Nageshwari Gandham; Lothar H Wieler; Christa Ewers; Niyaz Ahmed
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

8.  Effect of diabetes on mortality and length of hospital stay in patients with renal or perinephric abscess.

Authors:  Ming-Chung Ko; Allen Wen-Hsiang Chiu; Chih-Ching Liu; Chih-Kuang Liu; Lin-Chung Woung; Lai-King Yu; Chung-Yi Li
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

9.  Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran.

Authors:  Elahe Tajbakhsh; Parvin Ahmadi; Elham Abedpour-Dehkordi; Nazila Arbab-Soleimani; Faham Khamesipour
Journal:  Antimicrob Resist Infect Control       Date:  2016-04-01       Impact factor: 4.887

10.  Acute bacterial prostatitis and abscess formation.

Authors:  Dong Sup Lee; Hyun-Sop Choe; Hee Youn Kim; Sun Wook Kim; Sang Rak Bae; Byung Il Yoon; Seung-Ju Lee
Journal:  BMC Urol       Date:  2016-07-07       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.